How to use this tool
How to use this tool
InvestorGuide Stock Analysis
Will Shareholders Agree to Sell Genentech?
Excerpt from the InvestorGuide.com Stock of the Day on 2/2/2009
About six months ago, Swiss drugmaker Roche offered to buy out all of Genentech's remaining stock in a deal worth $44 billion. This equals about $89 per share. This represented a 9 percent premium at the time. The board of directors evaluated this offer and about a month later, rejected the bid saying the price significantly undervalued the company's worth and growth potential. Little else has occurred since, but on Friday, Roche took the deal directly to shareholders asking to buy their equity for $86.50 per share. The US biotech firm advised shareholders not to take action so it can review its current position and prepare a formal response. Investors and analysts expect an announcement within two weeks. By the end of Friday, Genentech's stock closed at $81.50, indicating investors are complying. Having been rejected once by the company, will Roche be rejected a second time by shareholders? More >
Excerpt from the InvestorGuide.com Stock of the Day on 2/2/2009
About six months ago, Swiss drugmaker Roche offered to buy out all of Genentech's remaining stock in a deal worth $44 billion. This equals about $89 per share. This represented a 9 percent premium at the time. The board of directors evaluated this offer and about a month later, rejected the bid saying the price significantly undervalued the company's worth and growth potential. Little else has occurred since, but on Friday, Roche took the deal directly to shareholders asking to buy their equity for $86.50 per share. The US biotech firm advised shareholders not to take action so it can review its current position and prepare a formal response. Investors and analysts expect an announcement within two weeks. By the end of Friday, Genentech's stock closed at $81.50, indicating investors are complying. Having been rejected once by the company, will Roche be rejected a second time by shareholders? More >
QLT (QLTI) Upgrades
Date
Analyst
Old Rating
New Rating
04/24/2008
RBC Capital
Sector Perform
Outperform
11/29/2007
Raymond James
Market Perform
Outperform
QLT (QLTI) Downgrades
Date
Analyst
Old Rating
New Rating
01/13/2009
RBC Capital
Outperform
Sector Perform
09/08/2008
Morgan Stanley
Equalweight
Underweight
12/09/2005
Morgan Stanley
Equal-Weight
Overweight
QLT (QLTI) New Coverage
Date
Analyst
Rating
No new coverage listed for QLTI at this time.
Special Offers
| Buy QLT for just $4 www.sharebuilder.com |
| What is Morningstar's rating for QLT? www.morningstar.com |
| Learn to spot opportunities in any market with a Risk-Free* 30-day trial from Investools. www.investools.com |
| Download a free Options Fundamentals Podcast, from The Options Industry Council. OptionsEducation.org |
QLTI Links
Guru Analysis:
MSN Money | Morningstar | Stock Consultant
Analyst Opinions:
Reuters | SmartMoney | MarketWatch | Nasdaq | BarChart | Schaeffers | CNN Money | TheStreet
Blogs:
SocialPicks | Topix.net | SeekingAlpha | Technorati | Ask.com
Message Boards:
ClearStation | RagingBull | Yahoo | Investopedia | FreeRealTime | StockHouse Trading Offers:
Buy QLTI for just $4
MSN Money | Morningstar | Stock Consultant
Analyst Opinions:
Reuters | SmartMoney | MarketWatch | Nasdaq | BarChart | Schaeffers | CNN Money | TheStreet
Blogs:
SocialPicks | Topix.net | SeekingAlpha | Technorati | Ask.com
Message Boards:
ClearStation | RagingBull | Yahoo | Investopedia | FreeRealTime | StockHouse Trading Offers:
Buy QLTI for just $4
